Brain radiation given sooner worked better with osimertinib
Original title: Optimal timing of stereotactic radiosurgery with first-line osimertinib in EGFR-mutant non-small cell lung cancer brain metastases: Immediate, early-consolidation and salvage strategies.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Both treatments are already used today, but this was only a look back at past records.
The short version
People who got focused brain radiation soon after starting osimertinib went longer before their brain tumors grew.
What was studied. Doctors at two hospitals looked back at records of people with lung cancer that had spread to the brain. All had an EGFR gene change, took osimertinib, and had 1 to 10 brain tumors. Three groups of 62 people each got focused radiation at a different time.
What they found. People who got radiation within 4 weeks went 27.0 months before the brain tumors grew. Waiting 4 to 12 weeks gave 22.5 months. Waiting until the tumors grew gave 15.7 months. Radiation within 4 weeks lowered the risk of brain tumor growth or death by 71%. Serious side effects were about the same in all three groups.
What this means, and what it doesn't
What it could mean: Getting focused brain radiation early may help hold brain tumors in check longer. If you have this kind of lung cancer, timing is worth asking your care team about.
What it doesn't mean: This was a look back at past records, not a planned trial. That means it cannot prove that earlier radiation caused the better results. It does not show what is right for every person. It is not a cure, and it does not apply to other kinds of lung cancer or other drugs.
Source: PubMed, September 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.